Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-21
2011-06-21
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S423000, C514S460000, C514S510000
Reexamination Certificate
active
07964614
ABSTRACT:
The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.
REFERENCES:
patent: 4287202 (1981-09-01), Horrobin
patent: 4902630 (1990-02-01), Bennett et al.
patent: 5003065 (1991-03-01), Merritt et al.
patent: 5272258 (1993-12-01), Siegel et al.
patent: 5500345 (1996-03-01), Soe et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 7030152 (2006-04-01), Ridker et al.
patent: 0 194 686 (1986-09-01), None
patent: 0 671 171 (1995-09-01), None
patent: 1 493 439 (2005-01-01), None
patent: 1 003 501 (2005-03-01), None
patent: 60139621 (1985-07-01), None
patent: 98/43630 (1998-10-01), None
patent: 98/47509 (1998-10-01), None
patent: WO 98 43630 (1998-10-01), None
Haverkate, et al., “Increased Levels of C-reactive Protein in Stable and Unstable Angina Pectoris,” Abstract #1048, American Heart Association, Supplement to Circulation, Abstracts from the 68thScientific Sessions, vol. 92, No. 8, Oct. 15, 1995.
Paul M. Ridker et al., “Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men,”The Lancet, vol. 351, No. 9096, pp. 88-92, Jan. 10, 1988.
M. A. Mendall et al., “C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study,”BMJ, vol. 312, pp. 1065-1069, Feb. 1996.
Russell P. Tracy et al., “Relationship of C-Reactive Protein to Risk of Cardiovascular Disease in the Elderly,”Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, No. 6, Jun. 1997.
Paul M. Ridker et al., “Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease,”Circulation, vol. 97, pp. 425-428, 1998.
Paul M. Ridker et al., “C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction,”Circulation, vol. 97, pp. 2007-2011, 1998.
Wolfgang Koenig, M.D., “C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men,”Circulation, vol. 99, pp. 237-242, 1999.
Paul M. Ridker et al., “Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women,”Circulation, vol. 98, pp. 731-733, 1998.
Paul M. Ridker et al., “Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels,”Circulation, vol. 98, pp. 839-844, 1998.
Giovanna Liuzzo, M.D. et al., “The Prognostic Value of C-Reactive aProtein and Serum Amyloid A Protein in Severe Unstable Angina,”The New England Journal of Medicine, vol. 331, No. 7, pp. 417-424, Aug. 18, 1994.
Attilio Maseri, M.D. et al., “Inflammation, Atherosclerosis, and Ischemic Events—Exploring the Hidden Side of the Moon,”The New England Journal of Medicine, vol. 336, No. 14, pp. 1014-1015, Apr. 3, 1997.
Shi-Jen Hwang, Ph.D. et al., “Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases,”Circulation, vol. 96, pp. 4219-4225, 1997.
Haverkate, F., et al., “C-reactive protein and cardiovascular disease,”Fibrinolysis&Proteolysis, 11 (Suppl. 1), pp. 133-134, 1997Biosis Abstract.
Di Minno, G., “Platelets, Prostaglandins and Thromboses,”G. Arterioscler, 3 (2), pp. 101-109, 1978,Biosis Abstract.
Kuller, L.H., et al., “Relation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control Study,”Am J Epidemiol, (1996), 144:537-547.
Haverkate, F., et al., “Production of C-Reactive Protein and Risk of Coronary Events in Stable and Unstable Angina,”Lancet, (1997), 349:462-466.
Lagrand, W.K., et al., “C-Reactive Protein Colocalizes with Complement in Human Hearts During Acute Myocardial Infarction,” (1997),Circulation, 95:97-103.
Ridker, et al.,New England Journal of Med.336, 973-979 (1997).
Ridker, et al., “Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men,”The New England Journal of Med, vol. 336, 973-979 (1997).
L.E.P. Rohde, et al., Cross-Sectional Study of Soluble Intercellular Adhesion Molecule-1 and Cardiovascular Risk Factors in Apparently Healthy Men,Vascular Biology, pp. 1595-1599, Jul. 1999.
Supplementary European Search Report for EP 98 91 7992, date of completion of search Nov. 17, 2000.
International Search Report for PCT/US 00/24251, date of completion of search Nov. 23, 2000.
M. Duenwald, “Body's Defender Goes on the Attack,”The New York Times Science Times, pp. D1 and D9, Jan. 22, 2002.
A. Comarow, “Telltale test for the heart, A key protein tracks inflamed arteries,”U.S. News&World Report, p. 52, Apr. 3, 2000.
R. Winslow, “Heart-Disease Sleuths Identify Prime Suspect: Inflammation of Artery, The Body's Efforts to Repair Irritated Lining of Vessel Can Backfire Disastrously,”Wall Street Journal, Oct. 7, 1999, pp. A1, A18-A19.
L. Johannes, “Cholesterol Drugs May Help Inflamed Arteries,”Wall Street Journal, Jul. 28, 2001.
A. Park, “The State of the Heart, If you thought cholesterol was all you had to worry about, better think again,”Time Magazine, Jul. 4, 2001.
S. Sternberg, “Cholesterol drug has wider benefit,”USA Today, p. 9D, Jul. 28, 2001.
M. Lasalandra, “Cholesterol-lowering drugs can cut heart-risk protein,”The Boston Herald, Jul. 4, 2001.
The Associated Press, “Blood Test May Help Heart Victims,”The New York Times, Jul. 27, 2001.
By Reuters, “Statins May Lower Protein Linked to Heart Disease,”The New York Times, Jul. 27, 2001.
By Reuters, “Protein Test, Drug May Cut Heart Attack Risk,”The New York Times, Jul. 27, 2001.
P. Peck, “Blood Test Could Save More from Heart Attack; Popular drugs that can hammer down cholesterol levels may very well be a panacea for preventing heart attacks, too,” Health.excite.com, Jul. 27, 2001.
“Drugs may help even if cholesterol levels low,”The Boston Herald, p. 6, Jul. 28, 2001.
The Associated Press, “Drugs Could Curb Blood Vessel Inflammation,”Science and Health, Jun. 28, 2001.
S. Thompson, et al., “Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris,” 1995,The New England Journal of Medicine, vol. 332, No. 10, pp. 635-641.
Doris Duke Foundation Press Release.
De Maat, M., et al., “No effect of pravastatin on C-Reactive Protein and fibrinogen levels,” 1999, 7thLeiden Fibrinolysis & Proteolysis Workshop, 13 Suppl. 1, pp. 36-69, Report #29.
Ridker et al., “Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events,”N. Engl. J. Med., vol. 347, No. 20, Nov. 14, 2002, pp. 1557-1565.
Ridker et al., “C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women,”N. Engl. J. Med., Mar. 23, 2000, vol. 342, No. 12, pp. 836-843.
Ridker et al., “Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events,”N. Engl. J. Med., Jun. 28, 2001, vol. 344, No. 26, pp. 1959-1965.
Mendall et al., “C-Reactive Protein: Relation to Total Mortality, Cardiovascular Mortality and Cardiovascular Risk Factors in Men,”European Heart Journal, 2000, vol. 21, pp. 1584-1590.
Hokanson et al., “Plasma triglyceride level is a risk factor for cardiovascular disease
Hennekens Charles H.
Ridker Paul
Hui San-ming
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
Systemic inflammatory markers as diagnostic tools in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systemic inflammatory markers as diagnostic tools in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic inflammatory markers as diagnostic tools in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2655761